REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 2,419,226	$ 2,096,039	$ 1,846,275
ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	131,248	128,422	122,765
Product
Disaggregation of Revenue [Line Items]
Revenue	2,372,538	2,042,025	1,783,498
Marketed by Company | Products excluding ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	2,241,290	1,913,603	1,660,733
Marketed by Company | Products excluding ALDURAZYME | United States
Disaggregation of Revenue [Line Items]
Revenue	771,314	684,284	657,700
Marketed by Company | Products excluding ALDURAZYME | Europe
Disaggregation of Revenue [Line Items]
Revenue	669,331	650,952	558,952
Marketed by Company | Products excluding ALDURAZYME | Latin America
Disaggregation of Revenue [Line Items]
Revenue	332,437	266,801	191,151
Marketed by Company | Products excluding ALDURAZYME | Rest of world
Disaggregation of Revenue [Line Items]
Revenue	468,208	311,566	252,930
Marketed by Sanofi | ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	$ 131,248	$ 128,422	$ 122,765